Skip to main content

Advertisement

Table 8 Chemotherapy regimen and overall survival of SCC transformation in MCTO of stage II, III and IV

From: Squamous cell carcinoma transformation in mature cystic teratoma of the ovary: a systematic review

Drug (n = 103) Univariate HR (95% CI) P value Stage-adjusted HR (95% CI) P value
Platinum derivatives (n = 92) 0.43 (0.21–0.87) 0.02* 0.41 (0.20–0.84) 0.02*
Taxanes (n = 29) 1.09 (0.61–1.98) 0.78 1.10 (0.60–2.00) 0.76
Vinca alkaloids (n = 21) 0.59 (0.30–1.20) 0.14 0.48 (0.23–1.01) 0.05
Alkylating agents (n = 15) 1.05 (0.53–2.09) 0.88 0.84 (0.38–1.84) 0.66
5-FU (n = 16) 0.77 (0.36–1.62) 0.50 0.82 (0.39–1.75) 0.61
Bleomycin (n = 36) 0.94 (0.55–1.61) 0.82 0.85 (0.48–1.50) 0.57
VP-16 (n = 12) 0.76 (0.33–1.78) 0.53 0.82 (0.35–1.92) 0.64
  1. Cox proportional hazard regression model analysis